Skip to main content

Advertisement

SpringerLink
Log in

Update on progressive supranuclear palsy

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

A better understanding of the challenges in the diagnosis of progressive supranuclear palsy (PSP), the most common atypical parkinsonian neurodegenerative disorder, has led to improving its diagnostic accuracy. Similarly, a better understanding of the role of tau mutations, mitochondrial complex I inhibitors, oxidative injury, and inflammation in neurodegeneration has led to an unraveling of potential risk factors for the development of PSP. These advances are explained in detail in this review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Nath U, Ben-Shlomo Y, Thomson RG, et al.: The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001, 124:1438–1449.

    Article  PubMed  CAS  Google Scholar 

  2. Steele JC, Richardson JC, Olszewski J: Progressive supranuclear palsy. Arch Neurol 1964, 10:333–359.

    PubMed  CAS  Google Scholar 

  3. Litvan I, Agid Y, Calne D, et al.: Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996, 47:1–9.

    PubMed  CAS  Google Scholar 

  4. Hauw JJ, Daniel SE, Dickson D, et al.: Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994, 44:2015–2019.

    PubMed  CAS  Google Scholar 

  5. Boeve BF, Lang AE, Litvan I: Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003, 54:S15-S19.

    Article  PubMed  Google Scholar 

  6. Litvan I, Campbell G, Mangone CA, et al.: Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. Brain 1997, 120:65–74.

    Article  PubMed  Google Scholar 

  7. Houlden H, Baker M, Morris HR, et al.: Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001, 56:1702–1706.

    PubMed  CAS  Google Scholar 

  8. Bird TD, Nochlin D, Poorkaj P, et al.: A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L). Brain 1999, 122:741–756.

    Article  PubMed  Google Scholar 

  9. Bugiani O, Murrell JR, Giaccone G, et al.: Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol 1999, 58:667–677.

    PubMed  CAS  Google Scholar 

  10. Morris HR, Katzenschlager R, Janssen JC, et al.: Sequence analysis of tau in familial and sporadic progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2002, 72:388–390.

    Article  PubMed  CAS  Google Scholar 

  11. Dickson DW, Bergeron C, Chin SS, et al.: Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002, 61:935–946.

    PubMed  CAS  Google Scholar 

  12. Arai T, Ikeda K, Akiyama H, et al.: Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann Neurol 2004, 55:72–79.

    Article  PubMed  CAS  Google Scholar 

  13. Kertesz A: Pick complex: an integrative approach to frontotemporal dementia: primary progressive aphasia, corticobasal degeneration, and progressive supranuclear palsy. Neurology 2003, 9:311–317.

    Article  Google Scholar 

  14. Schrag A, Ben-Shlomo Y, Quinn NP: Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999, 354:1771–1775.

    Article  PubMed  CAS  Google Scholar 

  15. Bower JH, Maraganore DM, McDonnell SK, Rocca WA: Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997, 49:1284–1288.

    PubMed  CAS  Google Scholar 

  16. Nath U, Ben-Shlomo Y, Thomson RG, et al.: Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 2003, 60:910–916.

    PubMed  CAS  Google Scholar 

  17. Litvan I, Mangone CA, McKee A, et al.: Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996, 60:615–620.

    PubMed  CAS  Google Scholar 

  18. Litvan I: Diagnosis and management of progressive supranuclear palsy. Semin Neurol 2001, 21:41–48.

    Article  PubMed  CAS  Google Scholar 

  19. Boeve BF, Silber MH, Parisi JE, et al.: Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 2003, 61:40–45.

    PubMed  CAS  Google Scholar 

  20. Goetz CG, Leurgans S, Lang AE, Litvan I: Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology 2003, 60:917–922. This study evaluates the value of using severe speech, gait, or swallowing disturbances as outcome measures in therapeutic trials in PSP.

    PubMed  Google Scholar 

  21. Siderowf A, Quinn NP: Progressive supranuclear palsy: setting the scene for therapeutic trials. Neurology 2003, 60:892–893.

    PubMed  Google Scholar 

  22. Boeve B, Dickson D, Duffy J, et al.: Progressive nonfluent aphasia and subsequent aphasic dementia associated with atypical progressive supranuclear palsy pathology. Eur Neurol 2003, 49:72–78.

    Article  PubMed  CAS  Google Scholar 

  23. Litvan I, Grimes DA, Lang AE, et al.: Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999, 246(suppl 2):II1-II5.

    Article  PubMed  Google Scholar 

  24. Robbins TW, James M, Owen AM, et al.: Cognitive deficits in progressive supranuclear palsy, Parkinson’s disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. J Neurol Neurosurg Psychiatry 1994, 57:79–88.

    Article  PubMed  CAS  Google Scholar 

  25. Litvan I, Bhatia KP, Burn DJ, et al.: SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 2003, 18:467–486. This article thoroughly and critically reviews available clinical diagnostic criteria.

    Article  PubMed  Google Scholar 

  26. Osaki Y, Ben-Shlomo Y, Lees AJ, et al.: Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord 2004, 19:181–189.

    Article  PubMed  Google Scholar 

  27. Kasashima S, Oda Y: Cholinergic neuronal loss in the basal forebrain and mesopontine tegmentum of progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol (Berlin) 2003, 105:117–124.

    CAS  Google Scholar 

  28. Litvan I, Baker M, Hutton M: Tau genotype: no effect on onset, symptom severity, or survival in progressive supranuclear palsy. Neurology 2001, 57:138–140.

    PubMed  CAS  Google Scholar 

  29. Albers DS, Augood SJ, Park LC, et al.: Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J Neurochem 2000, 74:878–881.

    Article  PubMed  CAS  Google Scholar 

  30. Odetti P, Garibaldi S, Norese R, et al.: Lipoperoxidation is selectively involved in progressive supranuclear palsy. J Neuropathol Exp Neurol 2000, 59:393–397.

    PubMed  CAS  Google Scholar 

  31. Caparros-Lefebvre D, Sergeant N, Lees A, et al.: Guadeloupean parkinsonism: a cluster of progressive supranuclear palsylike tauopathy. Brain 2002, 125:801–811. This study describes a cluster of patients with atypical parkinsonism in the French West Indies that closely resembles PSP.

    Article  PubMed  Google Scholar 

  32. Tasaki Y, Makino Y, Ohta S, Hirobe M: 1-Methyl-1,2,3,4-tetrahydroisoquioline, decreasing in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse, prevents parkinsonims-like behavior abnormalities. J Neurochem 1991, 57:1940–1943.

    Article  PubMed  CAS  Google Scholar 

  33. Yoshida M, Niwa T, Nagatsu T: Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinolone: the behavioral and biochemical changes. Neurosci Lett 1990, 119:109–113.

    Article  PubMed  CAS  Google Scholar 

  34. Lannuzel A, Michel PP, Abaul MJ, et al.: Neurotoxic effects of alkaloids from Annona muricata (sour-sop) on dopaminergic neurons: potential role in etiology of atypical parkinsonism in French West Indies [abstract]. Mov Disord 2000, 13(suppl 3):28.

    Google Scholar 

  35. Friedrich MJ: Pesticide study aids Parkinson research. JAMA 1999, 282:2200.

    Article  PubMed  CAS  Google Scholar 

  36. Dubois B, Beato R, Villalpando JM: Neuropsychological evaluation can contribute to the diagnosis of motion diseases. Rev Neurol (Paris) 2003, 159:S350-S356.

    Google Scholar 

  37. Rivaud-Pechoux S, Vidailhet M, Gallouedec G, et al.: Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. Neurology 2000, 54:1029–1032.

    PubMed  CAS  Google Scholar 

  38. Valls-Sole J: Neurophysiological characterization of parkinsonian syndromes. Neurophysiol Clin 2000, 30:352–367.

    Article  PubMed  CAS  Google Scholar 

  39. Valldeoriola F, Valls-Sole J, Tolosa ES, Marti MJ: Striated anal sphincter denervation in patients with progressive supranuclear palsy. Mov Disord 1995, 10:550–555.

    Article  PubMed  CAS  Google Scholar 

  40. Yekhlef F, Ballan G, Macia F, et al.: Routine MRI for the differential diagnosis of Parkinson’s disease, MSA, PSP, and CBD. J Neural Transm 2003, 110:151–169.

    Article  PubMed  CAS  Google Scholar 

  41. Savoiardo M: Differential diagnosis of Parkinson’s disease and atypical parkinsonian disorders by magnetic resonance imaging. Neurol Sci 2003, 24(suppl 1):S35-S37.

    Article  PubMed  Google Scholar 

  42. Seppi K, Schocke MF, Esterhammer R, et al.: Diffusionweighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003, 60:922–927.

    Article  PubMed  CAS  Google Scholar 

  43. Litvan I: Progressive supranuclear palsy. In Atypical Parkinsonian Disorders. Edited by Litvan I. Totowa, NJ: Humana Press; In press.

Download references

Author information

Authors and Affiliations

  1. Movement Disorder Program, Department of Neurology, University of Louisville School of Medicine, A Building, Room 113, 500 South Preston Street, 40202, Louisville, KY, USA

    Irene Litvan MD

Authors
  1. Irene Litvan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Litvan, I. Update on progressive supranuclear palsy. Curr Neurol Neurosci Rep 4, 296–302 (2004). https://doi.org/10.1007/s11910-004-0055-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-004-0055-z

Keywords

Search

Navigation